SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial ...
Kronos Worldwide, Inc. KRO reported fourth-quarter 2024 loss of 12 cents per share, wider than a loss of 5 cents per share a year ago. The Zacks Consensus Estimate was earnings of 11 cents per share.
Kronos Worldwide reports fourth quarter 2024 net loss of $13.2 million; full year 2024 net income rises to $86.2 million. Kronos Worldwide, Inc. announced a net loss of $13.2 million, or $.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback